Shares of DexCom, Inc. (NASDAQ:DXCM – Get Free Report) have received an average rating of “Moderate Buy” from the twenty-five analysts that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, twenty have assigned a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $89.08.
A number of brokerages have recently issued reports on DXCM. Deutsche Bank Aktiengesellschaft initiated coverage on DexCom in a research note on Tuesday, June 23rd. They set a “buy” rating and a $86.00 target price for the company. Canaccord Genuity Group set a $90.00 price target on DexCom and gave the company a “buy” rating in a research note on Monday, August 3rd. Benchmark upped their price objective on DexCom from $77.00 to $82.00 and gave the stock a “buy” rating in a report on Friday, July 31st. UBS Group set a $96.00 price objective on DexCom and gave the stock a “buy” rating in a report on Tuesday, July 28th. Finally, BTIG Research reiterated a “buy” rating and issued a $90.00 price objective (up from $80.00) on shares of DexCom in a research report on Friday, July 31st.
View Our Latest Research Report on DexCom
DexCom Price Performance
DexCom (NASDAQ:DXCM – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. The business had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The business’s revenue was up 13.1% compared to the same quarter last year. During the same period in the previous year, the business posted $0.48 earnings per share. As a group, analysts expect that DexCom will post 2.64 EPS for the current year.
Insider Activity at DexCom
In related news, EVP Jereme Sylvain sold 3,638 shares of the firm’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $83.27, for a total value of $302,936.26. Following the completion of the sale, the executive vice president owned 146,828 shares in the company, valued at $12,226,367.56. This trade represents a 2.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Brown sold 1,700 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $84.04, for a total transaction of $142,868.00. Following the completion of the sale, the executive vice president owned 99,885 shares of the company’s stock, valued at $8,394,335.40. This trade represents a 1.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 73,504 shares of company stock worth $5,651,332. 0.28% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Reflection Asset Management acquired a new stake in shares of DexCom during the 4th quarter valued at approximately $25,000. Ascentis Independent Advisors acquired a new stake in shares of DexCom in the 1st quarter worth approximately $25,000. MCF Advisors LLC acquired a new stake in shares of DexCom in the 4th quarter worth approximately $32,000. Wellington Grp LLC increased its stake in DexCom by 778.7% in the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 475 shares in the last quarter. Finally, Cassaday & Co Wealth Management LLC purchased a new position in DexCom in the 1st quarter valued at approximately $44,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.
About DexCom
DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.
The company’s products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.
Read More
- Five stocks we like better than DexCom
- Data Centers Got the AI Hype—But Office REITs May Get the Rent Hikes
- 2 Cybersecurity Stocks Breaking Out as AI Continues to Be a Tailwind
- 3 More AI Infrastructure Plays Beyond the Big Names
- CAVA Stock Slips: Sector Fear or Valuation Reality?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.
